Toinv - Sounds to me like you are using good logic. There will likely have to be some expanded science to give greater assurance to a potential purchaser. I understand that studies are underway to prove exactly that. The most intriguing thing to me is that the PSA numbers for the rockstar group fell below 1 and have stayed there. If that group is still responding now it would be about 55/56 weeks. In the de Bono JS et al article about aberaterone the PSA levels on average fell but not to the same degree as what looks like with the ZEN-3694 combo. So what is the difference? and will that be the difference that sets us apart?

As you know I am not a scientist so my comments are simply from a point of curiosity. From my understanding of the current trial the patients were only enrolled when they were no longer responding to aberaterone and now from both aberaterone and enzalutamide. If the company or an independent third party can prove that it is 3694 making the difference then things could start to get interesting for the shareholders.

tada